Compare Amylx Pharmaceuticals Inc (AMLX) vs GraniteShares 2x Long COIN Daily ETF (CONL) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.95 with a slight 0.61% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF has experienced significant volatility, losing 67% year-to-date according to 24/7 Wall Street (June 6, 2026), reflecting the amplified risks of daily-reset leverage on Coinbase stock performance.

The outlook remains highly speculative with potential for explosive gains if Bitcoin rallies toward $100,000, but investors face substantial volatility decay risks. Recent cryptocurrency momentum provides short-term catalysts, though the leveraged structure makes CONL suitable only for sophisticated traders comfortable with rapid capital erosion during market whipsaws.